Biocon Breaks Ground In Latin America Through Agreement In Brazil
Indian Firm Expands Partnership With Local Player Libbs
Having together achieved success with biosimilar trastuzumab in Brazil, Biocon and local player Libbs Farmaceutica have reached an agreement to offer the Indian firm’s generic formulations in the market.
You may also be interested in...
Fresenius Kabi has struck a deal with Brazilian organizations Fiocruz/Bio-Manguinhos and Bionovis to supply its Idacio biosimilar adalimumab rival to Humira for the next ten years.
Biocon is set to bolster its planned expansion into the MENA region through a partnership with Saudi firm Tabuk Pharmaceuticals, which will commercialize select Biocon generics in the Middle East.
Samsung Bioepis has launched its Ontruzant rival to Herceptin in Brazil, claiming the first biosimilar trastuzumab to be supplied to the country’s public health system for early and metastatic HER2-overexpressing breast cancer.